{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:47:37Z","timestamp":1765381657161,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.clinthera.2008.12.014","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T05:00:35Z","timestamp":1232686835000},"page":"2263-2271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects"],"prefix":"10.1016","volume":"30","author":[{"suffix":"III","given":"Herbert R.","family":"Henney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnston","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob D.","family":"Runyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.12.014_ceotherref1","unstructured":"Zanaflex (tizanidine hydrochloride) capsules and tablets [prescribing information]. Hawthorne, NY: Acorda Therapeutics, Inc; 2006."},{"key":"10.1016\/j.clinthera.2008.12.014_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","article-title":"Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders","volume":"53","author":"Wagstaff","year":"1997","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2008.12.014_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1476-5381.1982.tb09242.x","article-title":"Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiodazole (DS103-282)","volume":"76","author":"Davies","year":"1982","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.clinthera.2008.12.014_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1476-5381.1982.tb09234.x","article-title":"Reversible effects of tetanus toxin on striatal-evoked responses and [3H]-gammaaminobutyric acid release in the rat substantia nigra","volume":"76","author":"Collingridge","year":"1982","journal-title":"Br J Pharmacol."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2008.12.014_bib5","first-page":"S34","article-title":"Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebocontrolled trial","volume":"44","author":"Smith","year":"1994","journal-title":"Neurology"},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2008.12.014_bib6","first-page":"S70","article-title":"A doubleblind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis","volume":"44","year":"1994","journal-title":"Neurology."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2008.12.014_bib7","first-page":"S44","article-title":"Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury","volume":"44","author":"Nance","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2008.12.014_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archneur.1997.00550180049011","article-title":"Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis","volume":"54","author":"Nance","year":"1997","journal-title":"Arch Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2008.12.014_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0317167100038026","article-title":"Treatment of spasticity with tizanidine in multiple sclerosis","volume":"14","author":"Lapierre","year":"1987","journal-title":"Can J Neurol Sci."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2008.12.014_bib10","first-page":"S53","article-title":"Comparative profile of tizanidine in the management of spasticity","volume":"44","author":"Lataste","year":"1994","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2008.12.014_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1472-8206.1987.tb00581.x","article-title":"Pharmacokinetics of orally administered tizanidine in healthy volunteers","volume":"1","author":"Tse","year":"1987","journal-title":"Fundam Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2008.12.014_bib12","first-page":"9","article-title":"Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury","volume":"26","author":"Mathias","year":"1989","journal-title":"J Rehabil Res Dev."},{"key":"10.1016\/j.clinthera.2008.12.014_bib13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/jnnp.57.11.1355","article-title":"Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud)","volume":"57","author":"Emre","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2008.12.014_bib14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.clinthera.2006.09.014","article-title":"Effects of food on the single-dose pharmacokinetics\/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers","volume":"28","author":"Shah","year":"2006","journal-title":"Clin Ther."},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2008.12.014_bib15","first-page":"S29","article-title":"Pharmacokinetics and pharmacodynamics of tizanidine","volume":"44","author":"Roberts","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2008.12.014_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","article-title":"Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro","volume":"57","author":"Granfors","year":"2004","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2008.12.014_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2008.12.014_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","article-title":"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","volume":"76","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2008.12.014_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","article-title":"Rofecoxib is a potent inhibitor of cytochrome P450 1A2: Studies with tizanidine and caffeine in healthy subjects","volume":"62","author":"Backman","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2008.12.014_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: Studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2008.12.014_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0003-9993(99)90068-0","article-title":"Predictors of dysphagia after spinal cord injury","volume":"80","author":"Kirshblum","year":"1999","journal-title":"Arch Phys Med Rehabil."},{"key":"10.1016\/j.clinthera.2008.12.014_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00455-003-0511-y","article-title":"Cervical spinal cord injury and deglutition disorders","volume":"19","author":"Abel","year":"2004","journal-title":"Dysphagia."},{"key":"10.1016\/j.clinthera.2008.12.014_bib23","first-page":"22","article-title":"Dysphagia and multiple sclerosis","volume":"11","author":"Prosiegel","year":"2004","journal-title":"Int MS J."},{"key":"10.1016\/j.clinthera.2008.12.014_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2007.01660.x","article-title":"A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients","volume":"62","author":"Henney","year":"2008","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.clinthera.2008.12.014_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clinthera.2007.04.012","article-title":"Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A singledose, randomized, open-label, crossover study in healthy subjects","volume":"29","author":"Henney","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2008.12.014_bib26","first-page":"3","article-title":"1983 Metropolitan height and weight tables","volume":"64","year":"1983","journal-title":"Stat Bull Metrop Life Found"},{"key":"10.1016\/j.clinthera.2008.12.014_ceotherref2","unstructured":"European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice ICH Topic E6."},{"key":"10.1016\/j.clinthera.2008.12.014_ceotherref3","unstructured":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects."},{"year":"1995","series-title":"Department of Health and Human Services. Coding Symbols for Thesaurus of Adverse Reaction Terms","key":"10.1016\/j.clinthera.2008.12.014_bib29"},{"key":"10.1016\/j.clinthera.2008.12.014_ceotherref4","unstructured":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); January 2001."},{"key":"10.1016\/j.clinthera.2008.12.014_ceotherref5","unstructured":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); March 2003."},{"key":"10.1016\/j.clinthera.2008.12.014_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1185\/030079908X261113","article-title":"A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury","volume":"24","author":"Kamen","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2008.12.014_bib33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-6576.1995.tb04139.x","article-title":"The metabolic effects of oral tizanidine in healthy volunteers","volume":"39","author":"Taittonen","year":"1995","journal-title":"Acta Anaesthesiol Scand."},{"key":"10.1016\/j.clinthera.2008.12.014_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","article-title":"Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2","volume":"78","author":"Granfors","year":"2005","journal-title":"Clin Pharmacol Ther."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:02:15Z","timestamp":1762246935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808004499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0149291808004499"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}